ALNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alnylam Pharmaceuticals Inc (ALNY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows strong revenue growth and optimism for future sales, the recent price decline, bearish technical indicators, and missed earnings expectations suggest caution. The stock may be worth revisiting after stabilization or further positive developments.
The stock is in a bearish trend with the MACD histogram at -1.724 (negatively expanding), RSI_6 at 17.437 (oversold), and moving averages showing a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its S1 support level of 306.338, with further downside risk toward S2 at 292.77.
Strong revenue growth of 67.70% YoY in Q4
Non-GAAP net income surged to $169.8 million, reflecting improved profitability.
Positive long-term outlook with projected 2026 revenue between $5.3 billion and $5.8 billion.
Analysts maintain a generally positive outlook with multiple Buy and Outperform ratings.
Recent price decline of -4.28% in regular trading and -2.69% post-market.
Missed Q4 2025 EPS and revenue expectations.
Bearish technical indicators and oversold conditions.
Concerns over margin compression and elevated R&D expenses.
Lack of significant hedge fund or insider activity.
In Q4 2025, revenue increased by 67.70% YoY to $994.7 million, but net income dropped by -322.56% YoY to $186.4 million. EPS also fell by -310.77% YoY to $1.37, and gross margin declined to 73.09%, down -11.59% YoY.
Analysts maintain a generally positive outlook with multiple Buy and Outperform ratings. However, several firms have lowered their price targets, citing near-term growth and margin concerns. Price targets range from $351 to $530, indicating potential upside but also reflecting caution.
